Manufacturer Savings Cards vs. Compounded Cash-Pay: Which Actually Costs Less
NovoCare, LillyDirect, and compounded telehealth side by side. The honest cost comparison across doses — and how oral Wegovy at $149/month changes the calculus at starting doses.
Two cost-reduction pathways dominate GLP-1 access for patients paying out of pocket: manufacturer savings cards (NovoCare, LillyDirect) and compounded cash-pay telehealth. The math depends heavily on your insurance situation and dosing. Here's the honest comparison.
Manufacturer savings programs in 2026
| Program | Drug | Cash price | Eligibility |
|---|---|---|---|
| NovoCare (oral Wegovy) | Oral semaglutide 17/25mg | From $149/mo | No income requirement for starting dose; U.S. resident, no insurance coverage for drug |
| NovoCare (Wegovy injectable) | Semaglutide 2.4mg | ~$499/mo | No insurance coverage; income-based assistance programs available below 400% FPL |
| LillyDirect (Zepbound) | Tirzepatide 2.5-15mg | $399–549/mo by dose | No insurance coverage; U.S. resident; self-pay portal |
Oral semaglutide at $149/month for the starting dose is the most significant brand-name pricing development of 2026. The starting dose (17mg) is roughly equivalent in efficacy to lower injectable doses. Patients who tolerate oral semaglutide well can access brand-name treatment at a price point that competes with some compounded alternatives for the initial titration phase.
Compounded cash-pay in 2026
| Type | Typical price range | Format |
|---|---|---|
| Compounded injectable semaglutide | $150–300/mo | Multi-dose vial, weekly injection |
| Compounded injectable tirzepatide | $200–350/mo | Multi-dose vial, weekly injection |
| Compounded oral tirzepatide | $200–300/mo | Daily tablet or ODT |
| Sublingual/buccal semaglutide | $179–299/mo | Daily sublingual dose |
Which is actually cheaper?
At maintenance doses: compounded injectable is typically cheaper than brand-name programs. At starting doses: oral Wegovy's $149/month is competitive with lower-end compounded options. At high maintenance doses (sema 2.4mg, tirz 15mg): compounded remains substantially cheaper ($200-350 vs. $499-549 brand-name).
The non-price factors: compounded carries regulatory uncertainty (FDA 503B guidance pending); brand-name carries the manufacturing quality assurance and clinical trial evidence base; SHED's sublingual format at $299/month includes a $399/month price increase at the 7.5mg dose and above.
Verified telehealth providers
Compounded GLP-1 at cash-pay prices with clinical oversight.
Paid link Get started →Sublingual semaglutide from $297/mo. Note: price increases to $399/mo at 7.5mg+.
Paid link Get started →